Last €140.05 EUR
Change Today +0.051 / 0.04%
Volume 51.0
XP2 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 1:03 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (XP2) Snapshot

Open
€139.49
Previous Close
€140.00
Day High
€140.33
Day Low
€137.45
52 Week High
02/27/15 - €140.33
52 Week Low
11/7/14 - €65.74
Market Cap
8.9B
Average Volume 10 Days
257.2
EPS TTM
--
Shares Outstanding
63.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SALIX PHARMACEUTICALS LTD (XP2)

salix pharmaceuticals ltd (XP2) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (XP2) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (XP2) Top Compensated Officers

President of Medical, Research & Development ...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Consultant
Total Annual Compensation: $867.5K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (XP2) Key Developments

Salix Pharmaceuticals Ltd. Announces Executive Changes

Salix Pharmaceuticals Ltd. announced that Carolyn J. Logan retired as President and Chief Executive Officer, and as a director on January 30, 2015. Effective upon Ms. Logan's retirement, the board of directors of the company has appointed Thomas W. D'Alonzo as Acting President and Chief Executive Officer and William C. Bertrand, Jr. as Acting Chief Operating Officer. Mr. D'Alonzo, 71, has served as a member of the Board since May 2000 and has been the Chairman of the Board since June 2010. Additionally, Mr. D'Alonzo joined the board of directors of BioDelivery Sciences International, in April 2014. From 2005 until 2012, Mr. D'Alonzo served on the board of directors of Amarillo Biosciences Inc.

Salix Pharmaceuticals Promotes William P. Forbes to President, Medical, R&D and Chief Development Officer

Salix Pharmaceuticals Ltd. announced the promotion of William P. Forbes, PharmD to President, Medical, Research and Development and Chief Development Officer. Dr. Forbes previously served as Executive Vice President, Medical, Research and Development and Chief Development Officer. In his new role, Dr. Forbes' responsibilities will continue to include the development and post-marketing support of numerous products in a variety of therapeutic indications, including gastroenterology, hepatology and infectious disease. Dr. Forbes will report directly to Thomas W. D'Alonzo upon Mr. Dâ Alonzo, Acting Chief Executive Officer and Chairman of the Board.

Salix Pharmaceuticals Ltd. Announces Restatement of Consolidated Financial Statements for the Full Year 2013 and the First Three Quarters and Nine Months of 2014

Salix Pharmaceuticals Ltd. announced restatement of consolidated financial statements for the full year 2013 and the first three quarters of 2014. The Audit Committee of Board of Directors, in consultation with its outside advisors and management, has determined that the company’s previously issued consolidated financial statements for the full year 2013 and the first three quarters of 2014 require correction of certain errors and should no longer be relied upon. For the full year 2013, previously reported net product revenue, net income and diluted net income per share will be decreased by approximately $20.1 million, $11.8 million and $0.18 per share, respectively, for the full year 2013, as compared to originally reported amounts. Previously reported net product revenue will be increased by approximately $18.6 million, and net loss and diluted net loss per share will be decreased by approximately $8.9 million and $0.14 per share, respectively, for the three months ended March 31, 2014, as compared to originally reported amounts. Previously reported net product revenue, net income and diluted net income per share will be decreased by approximately $6.5 million, $3.4 million and $0.04 per share, respectively, for the three months ended June 30, 2014, as compared to originally reported amounts. For the nine months ended September 30, 2014, this would decrease previously reported net product revenue by $0.7 million and result in no change in net loss. Previously reported net product revenue will be decreased by approximately $12.8 million, and net loss and diluted net loss per share will be increased by approximately $5.5 million and $0.09 per share, respectively, for the three months ended September 30, 2014, as compared to originally reported amounts.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XP2:GR €140.05 EUR +0.051

XP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $70.25 USD -0.98
Jazz Pharmaceuticals PLC $170.09 USD -5.10
Lupin Ltd 1,747 INR +9.45
Ono Pharmaceutical Co Ltd ¥11,910 JPY +10.00
Santen Pharmaceutical Co Ltd ¥8,050 JPY +40.00
View Industry Companies
 

Industry Analysis

XP2

Industry Average

Valuation XP2 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.3x
Price/Book 19.0x
Price/Cash Flow 101.0x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.